News
ASMB
16.89
+0.48%
0.08
Weekly Report: what happened at ASMB last week (1021-1025)?
Weekly Report · 6d ago
Weekly Report: what happened at ASMB last week (1014-1018)?
Weekly Report · 10/21 09:07
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 10/16 12:10
Weekly Report: what happened at ASMB last week (1007-1011)?
Weekly Report · 10/14 09:08
Assembly Biosciences, Inc.'s (NASDAQ:ASMB) market cap surged US$16m last week, individual investors who have a lot riding on the company were rewarded
Simply Wall St · 10/12 14:19
Capitulation in biotech is near, as well as a rally – Piper Sandler
Seeking Alpha · 10/11 15:17
Weekly Report: what happened at ASMB last week (0930-1004)?
Weekly Report · 10/07 09:07
Weekly Report: what happened at ASMB last week (0923-0927)?
Weekly Report · 09/30 09:07
HC Wainwright & Co. Reiterates Neutral on Assembly Biosciences
Benzinga · 09/24 10:44
H.C. Wainwright Sticks to Their Hold Rating for Assembly Biosciences (ASMB)
TipRanks · 09/24 10:16
Assembly Biosciences' Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants
Benzinga · 09/23 17:39
Stocks Settle Mostly Lower on Chip Stock Weakness
NASDAQ · 09/23 12:39
ASSEMBLY BIOSCIENCES INC - ABI-5366 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE UP TO 70 DAYS
Reuters · 09/23 12:00
Weekly Report: what happened at ASMB last week (0916-0920)?
Weekly Report · 09/23 09:07
Stocks Moderately Lower Ahead of the Quarterly Triple-Witching Event
NASDAQ · 09/20 17:14
Stocks Settle Mostly Lower on Chip Stock Weakness
Barchart · 09/20 15:33
Assembly Biosciences Raised to Buy From Hold by Jefferies
Dow Jones · 09/20 12:34
Assembly Biosciences Price Target Raised to $35.00/Share From $2.00 by Jefferies
Dow Jones · 09/20 12:34
Jefferies Upgrades Assembly Biosciences to Buy, Raises Price Target to $35
Benzinga · 09/20 12:24
More
Webull provides a variety of real-time ASMB stock news. You can receive the latest news about Assembly Bioscie through multiple platforms. This information may help you make smarter investment decisions.
About ASMB
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.